BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28116522)

  • 1. Molecular characterization of CD44
    Da Cruz Paula A; Leitão C; Marques O; Rosa AM; Santos AH; Rêma A; de Fátima Faria M; Rocha A; Costa JL; Lima M; Lopes C
    Virchows Arch; 2017 Mar; 470(3):311-322. PubMed ID: 28116522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
    Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
    Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
    Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
    Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
    Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
    Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
    Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
    Lü X; Xu K; Lü H; Yin Y; Ma C; Liu Y; Li H; Suo Z
    Ultrastruct Pathol; 2011 Apr; 35(2):72-8. PubMed ID: 21299347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
    Gudadze M; Kankava Q; Mariamidze A; Burkadze G
    Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
    Li W; Liu F; Lei T; Xu X; Liu B; Cui L; Wei J; Guo X; Lang R; Fan Y; Gu F; Tang P; Zhang X; Fu L
    Pathol Res Pract; 2010 Dec; 206(12):828-34. PubMed ID: 20977976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
    So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N
    J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of HIF-1α in CD44+CD24-/low breast ductal carcinomas.
    Oliveira-Costa JP; Zanetti JS; Silveira GG; Soave DF; Oliveira LR; Zorgetto VA; Soares FA; Zucoloto S; Ribeiro-Silva A
    Diagn Pathol; 2011 Aug; 6():73. PubMed ID: 21824412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
    Liu C; Luo Y; Liu X; Lu P; Zhao Z
    Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
    Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
    J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
    Gudadze M; Kankava K; Mariamidze A; Mosidze T; Burkadze G
    Georgian Med News; 2013 Sep; (222):50-7. PubMed ID: 24099815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
    de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
    J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncovering the genomic heterogeneity of multifocal breast cancer.
    Desmedt C; Fumagalli D; Pietri E; Zoppoli G; Brown D; Nik-Zainal S; Gundem G; Rothé F; Majjaj S; Garuti A; Carminati E; Loi S; Van Brussel T; Boeckx B; Maetens M; Mudie L; Vincent D; Kheddoumi N; Serra L; Massa I; Ballestrero A; Amadori D; Salgado R; de Wind A; Lambrechts D; Piccart M; Larsimont D; Campbell PJ; Sotiriou C
    J Pathol; 2015 Aug; 236(4):457-66. PubMed ID: 25850943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.